HomeStock ScreenerPiramal Pharma

Piramal Pharma Share Price | Piramal Pharma Stock Screener

PPLPHARMA Pharmaceuticals
Share Price NSE
₹181.27
▲ 0.44 (0.24%)
2026-07-24 00:00:00
Share Price BSE
₹181.15
▲ 0.30 (0.17%)
2026-07-24 00:00:00
As of July 24, 2026, the Piramal Pharma share price (NSE: PPLPHARMA) is ₹181.27 on NSE and ₹181.15 on BSE, up 0.24% from the previous close, with shares trading between ₹178.24 and ₹182.32, and a 52-week range of ₹133.27–₹208.00. Analyse PPLPHARMA share price charts and track historical price performance. Use the Piramal Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Piramal Pharma Market Cap ₹24,604.64 Cr.
PPLPHARMA P/E Ratio (TTM) -73.04
Piramal Pharma P/B Ratio 2.92
EPS (TTM) ₹-2.46
Dividend Yield -
Debt to Equity 0.65
PPLPHARMA 52 Week High ₹208.00
Piramal Pharma 52 Week Low ₹133.27
Operating Margin 10.00%
Profit Margin -0.32%
PPLPHARMA Revenue (TTM) ₹2,811.00
EBITDA ₹344.00
Net Income ₹-9.00
Total Assets ₹17,965.00
Total Equity ₹8,163.00

Piramal Pharma Share Price Chart

Screen Piramal Pharma share price with an interactive chart. Analyse PPLPHARMA price trends and volatility across different timeframes.

Piramal Pharma Company Profile - Fundamental Screener

Screen Piramal Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for PPLPHARMA shares.
Piramal Pharma Limited is an Indian pharmaceutical company incorporated in 2020. It offers a diverse portfolio of products and services through 17 global facilities and distribution in over 100 countries. The company operates through three main segments: an integrated Contract Development and Manufacturing Organization (CDMO) business, a Complex Hospital Generics...more
Sector Healthcare
Industry Pharmaceuticals
Sub-Sector Pharmaceuticals
Segment E
Chairperson/CEO Nandini Piramal
ISIN INE0DK501011

Piramal Pharma Balance Sheet Screener

Screen PPLPHARMA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
Item 2026 2025 2024 2023 2022 2021
Assets
Total Assets 17,965 15,678 15,312 14,523 12,797 10,900
Current Assets 7,192 5,797 5,465 4,836 4,067 3,649
Fixed Assets 8,684 8,133 7,990 7,469 6,879 6,106
Liabilities
Total Liabilities 0 0 0 0 0 0
Current Liabilities 5,044 3,786 3,031 3,906 3,067 2,805
Non-Current Liabilities 0 0 0 0 0 0
Shareholders' Equity
Total Equity 8,163 8,126 7,911 6,774 6,697 5,605
Share Capital 1,327 1,324 1,323 1,193 1,186 995
Reserves & Surplus 6,836 6,801 6,588 5,580 5,511 4,610

Piramal Pharma Income Statement Screener - Profit & Revenue Analysis

Screen Piramal Pharma income statement and profit fundamentals. Analyze PPLPHARMA quarterly results, revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Piramal Pharma share price evaluation.
Item 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar 2022-Dec 2022-Sept
Revenue 2,811 2,193 2,124 2,031 2,812 2,233 2,320 1,993 2,591 2,034 1,980 1,802 2,196 1,814 1,777
Expenses 2,467 1,985 1,885 1,827 2,193 1,867 1,900 1,747 2,053 1,723 1,646 1,617 1,812 1,629 1,554
EBITDA 344 208 239 204 619 367 420 246 538 312 334 185 384 185 223
Operating Profit % 10.00% 7.00% 8.00% 6.00% 20.00% 15.00% 15.00% 10.00% 20.00% 12.00% 14.00% 8.00% 16.00% 5.00% 10.00%
Depreciation 218 213 203 197 243 197 192 185 196 186 185 174 184 164 166
Interest 83 89 82 86 104 103 108 107 114 106 110 119 104 95 83
Profit Before Tax 43 -94 -46 -79 273 67 120 -45 228 19 40 -107 95 -74 -26
Tax 52 42 53 3 119 63 98 44 126 9 35 -9 45 17 11
Net Profit -9 -136 -99 -82 154 4 23 -89 101 10 5 -99 50 -90 -37
EPS -0.07 -1.03 -0.75 -0.62 1.16 0.03 0.17 -0.67 0.77 0.08 0.04 -0.83 0.42 -0.76 -0.31

Piramal Pharma Cash Flow Screener - Liquidity Fundamentals

Screen PPLPHARMA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March
Operating Activities 1,653 892 1,005 484 766 598
Investing Activities -820 -488 -416 -1,334 -1,737 -4,464
Financing Activities -39 -441 -422 818 794 3,977
Net Cash Flow 794 -37 166 -32 -177 110

Piramal Pharma Shareholding Pattern Screener

See Piramal Pharma shareholding pattern with promoter, FII, and DII holdings. Check Piramal Pharma promoter holding and ownership changes for PPLPHARMA on TickJournal.
Item 2026-Mar 2026-Jun 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun
Promoter Holding 34.86% 34.80% 34.95% 34.86% 34.86% 34.86% 35.02% 34.95%
FII Holding 30.18% 12.52% 31.49% 30.86% 30.27% 29.66% 30.59% 31.42%
DII Holding 15.61% 14.57% 14.78% 14.26% 14.89% 15.69% 12.12% 12.95%
Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 13.74% 14.54% 13.11% 14.07% 14.12% 14.11% 15.13% 13.94%
Other Holding 5.61% 23.57% 5.66% 5.95% 5.86% 5.69% 7.14% 6.74%
Shareholder Count 450,661 461,096 432,843 458,430 462,511 453,830 297,996 306,398

Piramal Pharma Share Dividend Screener - Share Yield Analysis

Check Piramal Pharma dividend history with payout and yield data. View Piramal Pharma dividend details including ex-dates and amounts for PPLPHARMA stock.
Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹0.14 0.10%
2024-March ₹0.11 0.05%
2023-March ₹0.00 0.00%
2022-March ₹0.56 0.84%
2021-March ₹0.00 0.00%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Piramal Pharma Stock Index Membership

See which indices include Piramal Pharma stock. Check PPLPHARMA index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX BSEIPO
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
BSE INDEX SMLSEL
NIFTY 500
NIFTY ALPHA 50
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MULTI MFG
NIFTY SMLCAP 100
NIFTY SMLCAP 250
NIFTY SMLCAP 50
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP

Piramal Pharma Market Events Screener - Corporate Actions

Get Piramal Pharma corporate actions including splits, bonuses, and buybacks. Check Piramal Pharma stock events that may affect PPLPHARMA share price.
Announcement Date Record Date Event Type Information Price Impact
2026-07-30 2026-07-30 Annual General Meeting NA 6.39%
2026-04-28 2026-04-28 Quarterly Result Announcement NA 14.47%
2026-01-28 2026-01-28 Quarterly Result Announcement NA -9.31%
2025-11-05 2025-11-05 Quarterly Result Announcement NA -1.56%
2025-07-30 2025-07-30 Annual General Meeting NA 2.83%
2025-07-28 2025-07-28 Quarterly Result Announcement NA -6.75%
2025-07-16 2025-07-16 Dividend ₹ 0.14 /share 0.61%
2025-05-14 2025-05-14 Quarterly Result Announcement NA -0.02%
2025-01-28 2025-01-28 Quarterly Result Announcement NA 1.24%
2024-10-23 2024-10-23 Quarterly Result Announcement NA -2.78%
2024-07-26 2024-07-26 Annual General Meeting NA 5.86%
2024-07-12 2024-07-12 Dividend ₹ 0.11 /share 2.40%
2023-08-02 2023-08-02 Rights 5:46 1.87%

Piramal Pharma Competitors Screener - Peer Comparison

Screen PPLPHARMA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 470,726 40.78 61,674 12.69% 11,565 68.02
Divis Laboratories 194,588 75.69 11,067 13.95% 2,568 71.98
Torrent Pharmaceuticals 191,732 79.19 13,886 20.34% 2,138 66.68
Cipla 115,724 30.16 29,045 2.24% 3,870 52.50
Zydus Life Science 115,023 22.33 27,658 17.64% 5,026 58.19
Lupin 114,985 21.16 29,039 26.75% 5,356 63.60
Mankind Pharma 106,532 54.68 14,636 14.85% 1,938 60.75
Dr Reddys Laboratories 100,661 24.56 35,059 3.90% 4,158 32.84
Aurobindo Pharma 90,892 25.88 33,385 3.21% 3,376 58.93
Laurus Labs 86,010 94.61 6,868 22.01% 890 67.71

Piramal Pharma Company Announcements - News Screener

Screen PPLPHARMA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
Date Update Actions
2026-07-25 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-07-25 Board Meeting Intimation for Considering And Approving The Unaudited Financial Results (Standalone And Consolidated) Of The Company For Quarter Ended 30Th June 2026. -
2026-07-22 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-07-09 Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-07-04 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-07-03 Business Responsibility and Sustainability Reporting (BRSR) -
2026-07-03 Reg. 34 (1) Annual Report. -
2026-07-03 Notice Of The 6Th Annual General Meeting And Annual Report For The Financial Year 2025-26 -
2026-06-29 Closure of Trading Window -
2026-06-23 Clarification On News Item Appearing On NDTV Profit Captioned - "Piramal Pharma Share Price Spikes Over 10% - What Is Driving The Rally?" -
2026-06-23 Clarification sought from Piramal Pharma Ltd -
2026-06-19 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-06-05 Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS -
2026-06-03 Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-06-01 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-05-22 Compliances-Reg.24(A)-Annual Secretarial Compliance -
2026-05-19 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-05-18 Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Successful Closure Of US FDA Inspection At Piramal PharmaS Manufacturing Facility Located At Digwal Telangana India -
2026-05-10 Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-05-04 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -